Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Fiche publication
Date publication
avril 2016
Journal
Journal of the neurological sciences
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G
Lien Pubmed
Résumé
Memantine, an uncompetitive antagonist of N-methyl-D-aspartate (NMDA)-type glutamate receptors that was approved for the treatment of moderate to severe Alzheimer's disease, has been negatively evaluated for the treatment of cognitive disorders of multiple sclerosis, but these studies were conducted only during short-term administration and on a heterogeneous group of patients with different forms of the disease. In addition, many adverse reactions were observed in these patients.
Mots clés
Adult, Cognition Disorders, chemically induced, Dizziness, chemically induced, Double-Blind Method, Excitatory Amino Acid Antagonists, adverse effects, Female, Headache, chemically induced, Humans, Male, Memantine, adverse effects, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, diagnosis, Treatment Outcome, Young Adult
Référence
J. Neurol. Sci.. 2016 Apr 15;363:69-76